Wellstat Therapeutics Corp. has described compounds for co-delivery of uridine and ketoleucine with high bioavailability reported to be useful for the treatment of muscle atrophy, sarcopenia and cachexia.
Maze Therapeutics has patented apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, HIV-associated nephropathy, lupus nephritis and sepsis.
Aliad Biopharma Co. Ltd. has presented compounds acting as autophagy inducer, mTOR complex 1 (mTORC1) and mTORC2 inhibitors reported to be useful for the treatment of autism spectrum disorders, Alzheimer’s disease, epilepsy, fragile-X syndrome, macrocephaly and tuberous sclerosis.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has identified Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
Marvel Biotechnology Inc. has synthesized purine compounds acting as adenosine A2A receptor (ADORA2A) antagonists reported to be useful for the treatment of cancer, depression, multiple sclerosis, nonalcoholic steatohepatitis (NASH), scleroderma, attention deficit hyperactivity disorder (ADHD), and Parkinson's and Alzheimer's diseases.
Lanzhou University and Tencent Technology (Shenzhen) Co. Ltd. have patented glucagon receptor (GCGR) antagonists reported to be useful for the treatment of diabetes and hyperglycemia.
Galecto Biotech AB has discovered β-D-galactopyranose compounds acting as galectin-1 (LGALS1) and/or galectin-3 (LGALS3) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis and cardiovascular, eye, metabolic, cerebrovascular and inflammatory disorders, among other disorders.
Qilu Regor Therapeutics Inc. has identified (hetero)arylamino-cyclohexyl-sulfonyl derivatives acting as C-C chemokine receptor type 6 (CCR6) antagonists reported to be useful for the treatment of inflammatory bowel disease, Crohn's disease and ulcerative colitis.
RSS